Skip to main content
SpringerLink
Log in
Book cover

Textbook of Pancreatic Cancer pp 1267–1280Cite as

Role of Ablation Technologies in Locally Advanced Pancreatic Cancer

  • Chapter
  • First Online:

Abstract

Locally advanced pancreatic cancer is one of the most common presentation of the disease at the time of diagnosis. In this case, a systemic treatment with chemotherapy (with or without radiotherapy) is the standard of care with the aim to pursue conversion to radical surgery. However, due to the biology of the disease and the complex anatomy of the pancreatic region, this is achievable in up to a third of patients. The vast majority, indeed, do not receive surgical exploration due to persistent local vascular infiltration not amenable to radical resection. In this scenario, there is been a growing interest on tumor ablation to obtain a local control of the disease. In the recent years a robust amount of studies reported interesting results with pancreatic cancer ablation, in terms of safety, feasibility, and, marginally, efficacy. This book chapter presents the current evidence supporting the adoption of these technologies, with hints of indications, technique, and results.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018: cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.

    PubMed  Google Scholar 

  2. van Veldhuisen E, et al. Locally advanced pancreatic cancer: work-up, staging, and local intervention strategies. Cancers. 2019;11:976.

    PubMed Central  Google Scholar 

  3. Chun YS, Pawlik TM, Vauthey J-N. Eighth edition of the AJCC cancer staging manual: pancreas and hepatobiliary cancers. Ann Surg Oncol. 2018;25:845–7.

    PubMed  Google Scholar 

  4. Suker M, et al. FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis. Lancet Oncol. 2016;17:801–10.

    CAS  PubMed  PubMed Central  Google Scholar 

  5. Hammel P, et al. Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC). J Clin Oncol. 2018;36:204.

    Google Scholar 

  6. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Pancreatic adenocarcinoma. NCCN Guidelines version 3.2017.

    Google Scholar 

  7. Reni M, et al. Selecting patients for resection after primary chemotherapy for non-metastatic pancreatic adenocarcinoma. Ann Oncol. 2017;28:2786–92.

    CAS  PubMed  Google Scholar 

  8. Gemenetzis G, et al. Survival in locally advanced pancreatic cancer after neoadjuvant therapy and surgical resection. Ann Surg. 2019;270:340–7.

    PubMed  Google Scholar 

  9. Marthey L, et al. FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. 2015;22:295–301.

    CAS  PubMed  Google Scholar 

  10. Maggino L, et al. Outcomes of primary chemotherapy for borderline resectable and locally advanced pancreatic ductal adenocarcinoma. JAMA Surg. 2019;154(10):932–42. https://doi.org/10.1001/jamasurg.2019.2277.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Mollberg N, et al. Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg. 2011;254:882–93.

    PubMed  Google Scholar 

  12. Bachellier P, Addeo P, Faitot F, Nappo G, Dufour P. Pancreatectomy with arterial resection for pancreatic adenocarcinoma: how can it be done safely and with which outcomes? Ann Surg. 2020;271(5):932–40. https://doi.org/10.1097/SLA.0000000000003010.

    Article  PubMed  Google Scholar 

  13. Cannella R, Borhani AA, Zureikat AH, Tublin ME. Appleby procedure (distal pancreatectomy with celiac artery resection) for locally advanced pancreatic carcinoma: indications, outcomes, and imaging. AJR Am J Roentgenol. 2019:1–10. https://doi.org/10.2214/AJR.18.20887.

  14. Tong H, Fan Z, Liu B, Lu T. The benefits of modified FOLFIRINOX for advanced pancreatic cancer and its induced adverse events: a systematic review and meta-analysis. Sci Rep. 2018;8:8666.

    PubMed  PubMed Central  Google Scholar 

  15. Baldini C, et al. Safety and efficacy of FOLFIRINOX in elderly patients with metastatic or locally advanced pancreatic adenocarcinoma: a retrospective analysis. Pancreatology. 2017;17:146–9.

    CAS  PubMed  Google Scholar 

  16. D’Onofrio M, et al. Percutaneous radiofrequency ablation of unresectable locally advanced pancreatic cancer: preliminary results. Technol Cancer Res Treat. 2017;16:285–94.

    PubMed  Google Scholar 

  17. Giardino A, et al. Immunomodulation after radiofrequency ablation of locally advanced pancreatic cancer by monitoring the immune response in 10 patients. Pancreatology. 2017;17:962–6.

    PubMed  Google Scholar 

  18. He C, Wang J, Sun S, Zhang Y, Li S. Immunomodulatory effect after irreversible electroporation in patients with locally advanced pancreatic cancer. J Oncol. 2019;2019:1–13.

    Google Scholar 

  19. Zhao J, et al. Irreversible electroporation reverses resistance to immune checkpoint blockade in pancreatic cancer. Nat Commun. 2019;10:899.

    PubMed  PubMed Central  Google Scholar 

  20. Scheffer HJ, et al. Irreversible electroporation of locally advanced pancreatic cancer transiently alleviates immune suppression and creates a window for antitumor T cell activation. Oncoimmunology. 2019;8:1652532.

    PubMed  PubMed Central  Google Scholar 

  21. Carrafiello G, et al. Microwave ablation of pancreatic head cancer: safety and efficacy. J Vasc Interv Radiol. 2013;24:1513–20.

    PubMed  Google Scholar 

  22. Ruarus A, Vroomen L, Puijk R, Scheffer H, Meijerink M. Locally advanced pancreatic cancer: a review of local ablative therapies. Cancers. 2018;10:16.

    PubMed Central  Google Scholar 

  23. Fegrachi S, et al. Safety of radiofrequency ablation in patients with locally advanced, unresectable pancreatic cancer: a phase II study. Eur J Surg Oncol. 2019;45:2166–72.

    PubMed  Google Scholar 

  24. D’Onofrio M, et al. Percutaneous ablation of pancreatic cancer. World J Gastroenterol. 2016;22:9661.

    PubMed  PubMed Central  Google Scholar 

  25. Fegrachi S, et al. Radiofrequency ablation of the pancreas with and without intraluminal duodenal cooling in a porcine model. J Surg Res. 2013;184:867–72.

    PubMed  Google Scholar 

  26. Crinò SF, et al. EUS-guided radiofrequency ablation (EUS-RFA) of solid pancreatic neoplasm using an 18-gauge needle electrode: feasibility, safety, and technical success. J Gastrointestin Liver Dis. 2018;27:67–72.

    PubMed  Google Scholar 

  27. Paiella S, et al. Palliative therapy in pancreatic cancer—interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol. 2018;3:80.

    PubMed  PubMed Central  Google Scholar 

  28. Paiella S, et al. Ablation treatments in unresectable pancreatic cancer. Minerva Chir. 2019;74:263–9.

    PubMed  Google Scholar 

  29. Moris D, et al. Systematic review of surgical and percutaneous irreversible electroporation in the treatment of locally advanced pancreatic cancer. Ann Surg Oncol. 2019;26:1657–68.

    PubMed  Google Scholar 

  30. Martin RCG. Use of irreversible electroporation in unresectable pancreatic cancer. Hepatobiliary Surg Nutr. 2015;4:211–5.

    PubMed  PubMed Central  Google Scholar 

  31. Martin RC, Irreversible G. Electroporation of locally advanced pancreatic head adenocarcinoma. J Gastrointest Surg. 2013;17:1850–6.

    PubMed  Google Scholar 

  32. Young SJ. Irreversible electroporation and the pancreas: what we know and where we are going? World J Gastrointest Surg. 2015;7:138.

    PubMed  PubMed Central  Google Scholar 

  33. Paiella S, et al. Local ablative strategies for ductal pancreatic cancer (radiofrequency ablation, irreversible electroporation): a review. Gastroenterol Res Pract. 2016;2016:1–10.

    Google Scholar 

  34. Field W, Rostas JW, Martin RCG. Quality of life assessment for patients undergoing irreversible electroporation (IRE) for treatment of locally advanced pancreatic cancer (LAPC). Am J Surg. 2019;218:571–8.

    PubMed  Google Scholar 

  35. Holland MM, et al. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. HPB. 2019;21:1024–31.

    PubMed  Google Scholar 

  36. He C, et al. Irreversible electroporation versus radiotherapy after induction chemotherapy on survival in patients with locally advanced pancreatic cancer: a propensity score analysis. BMC Cancer. 2019;19:394.

    PubMed  PubMed Central  Google Scholar 

  37. Martin RCG, McFarland K, Ellis S, Velanovich V. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival. Ann Surg Oncol. 2013;20:443–9.

    Google Scholar 

  38. Leen E, et al. Percutaneous irreversible electroporation with systemic treatment for locally advanced pancreatic adenocarcinoma. J Gastrointest Oncol. 2018;9:275–81.

    PubMed  PubMed Central  Google Scholar 

  39. Belfiore MP, et al. Percutaneous CT-guided irreversible electroporation followed by chemotherapy as a novel neoadjuvant protocol in locally advanced pancreatic cancer: our preliminary experience. Int J Surg. 2015;21:S34–9.

    PubMed  Google Scholar 

  40. Kluger MD, et al. Single-institution experience with irreversible electroporation for T4 pancreatic cancer: first 50 patients. Ann Surg Oncol. 2016;23:1736–43.

    PubMed  Google Scholar 

  41. MåNsson C, et al. Percutaneous irreversible electroporation as first-line treatment of locally advanced pancreatic cancer. Anticancer Res. 2019;39:2509–12.

    PubMed  Google Scholar 

  42. Tian G, Liu X, Zhao Q, Xu D, Jiang T. Irreversible electroporation in patients with pancreatic cancer: how important is the new weapon? Biomed Res Int. 2018;2018:1–12.

    Google Scholar 

  43. Chauffert B, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19:1592–9.

    CAS  PubMed  Google Scholar 

  44. Dromi S, et al. Pulsed-high intensity focused ultrasound and low temperature sensitive liposomes for enhanced targeted drug delivery and antitumor effect. Clin Cancer Res. 2007;13:2722–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Ierardi AM, et al. Percutaneous ablation therapies of inoperable pancreatic cancer: a systematic review. Ann Gastroenterol. 2015;28:431–9.

    PubMed  PubMed Central  Google Scholar 

  46. Gao H-F, et al. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology. 2013;60:1906–10.

    PubMed  Google Scholar 

  47. Mir LM, et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator™ by means of invasive or non-invasive electrodes. Eur J Cancer Suppl. 2006;4:14–25.

    CAS  Google Scholar 

  48. Granata V, et al. Electrochemotherapy in locally advanced pancreatic cancer: preliminary results. Int J Surg. 2015;18:230–6.

    CAS  PubMed  Google Scholar 

  49. Di Matteo FM, et al. Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. Gastrointest Endosc. 2018;88:168–174.e1.

    PubMed  Google Scholar 

  50. Jiang T, Deng Z, Li J, Tian G. Pancreatic cancer: does it work if EUS and laser ablation get married? Endosc Ultrasound. 2018;7:207.

    PubMed  PubMed Central  Google Scholar 

  51. Axelsson J, et al. Initial findings of immunostimulating interstitial laser thermotherapy of solid tumours. J Clin Stud. 2017;9:28–31.

    Google Scholar 

  52. Flak RV, et al. Treatment of locally advanced pancreatic cancer with irreversible electroporation – a Danish single center study of safety and feasibility. Scand J Gastroenterol. 2019;54:252–8.

    PubMed  Google Scholar 

  53. Scheffer HJ, et al. Irreversible electroporation for nonthermal tumor ablation in the clinical setting: a systematic review of safety and efficacy. J Vasc Interv Radiol. 2014;25:997–1011.

    PubMed  Google Scholar 

  54. Ekici Y, Tezcaner T, Aydın HO, Boyvat F, Moray G. Arterial complication of irreversible electroporation procedure for locally advanced pancreatic cancer. World J Gastrointest Oncol. 2016;8:751.

    PubMed  PubMed Central  Google Scholar 

  55. Frigerio I, Giardino A, Grielli R, Regi P, Scopelliti F. RFA and pancreatic cancer: 5 years experience from a single center. Eur J Surg Oncol EJSO. 2013;39:S46.

    Google Scholar 

  56. Girelli R, et al. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013;398:63–9.

    PubMed  Google Scholar 

  57. Paiella S, et al. Role of local ablative techniques (radiofrequency ablation and Irreversible electroporation) in the treatment of pancreatic cancer. Updat Surg. 2016;68:307–11.

    Google Scholar 

  58. Månsson C, Brahmstaedt R, Nilsson A, Nygren P, Karlson B-M. Percutaneous irreversible electroporation for treatment of locally advanced pancreatic cancer following chemotherapy or radiochemotherapy. Eur J Surg Oncol EJSO. 2016;42:1401–6.

    PubMed  Google Scholar 

  59. Narayanan G, et al. Percutaneous image-guided irreversible electroporation for the treatment of unresectable, locally advanced pancreatic adenocarcinoma. J Vasc Interv Radiol. 2017;28:342–8.

    PubMed  Google Scholar 

  60. Zhang Y, et al. Percutaneous irreversible electroporation for ablation of locally advanced pancreatic cancer: experience from a Chinese institution. Pancreas. 2017;46:e12–4.

    PubMed  Google Scholar 

  61. Ning Z, et al. HIFU is safe, effective, and feasible in pancreatic cancer patients: a monocentric retrospective study among 523 patients. Onco Targets Ther. 2019;12:1021–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Sofuni A, et al. Safety trial of high-intensity focused ultrasound therapy for pancreatic cancer. World J Gastroenterol. 2014;20:9570–7.

    PubMed  PubMed Central  Google Scholar 

  63. Sung HY, et al. Long-term outcome of high-intensity focused ultrasound in advanced pancreatic cancer. Pancreas. 2011;40:1080–6.

    PubMed  Google Scholar 

  64. Martin RC, Philips P, Ellis S, Hayes D, Bagla S. Irreversible electroporation of unresectable soft tissue tumors with vascular invasion: effective palliation. BMC Cancer. 2014;14:540.

    PubMed  PubMed Central  Google Scholar 

  65. Li Y-J, Huang G-L, Sun X-L, Zhao X-C, Li Z-G. The combination therapy of high-intensity focused ultrasound with radiotherapy in locally advanced pancreatic carcinoma. World J Surg Oncol. 2016;14:60.

    PubMed  PubMed Central  Google Scholar 

  66. Paiella S, et al. Safety and feasibility of irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer: results of a prospective study. Dig Surg. 2015;32:90–7.

    PubMed  Google Scholar 

  67. Martin RCG, et al. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy. Ann Surg. 2015;262:486–94.

    PubMed  Google Scholar 

  68. Lambert L, et al. Treatment of locally advanced pancreatic cancer by percutaneous and intraoperative irreversible electroporation: general hospital cancer center experience. Neoplasma. 2016;63:269–73. https://doi.org/10.4149/213_150611N326.

    Article  CAS  PubMed  Google Scholar 

  69. Bhutiani N, et al. Safety, efficacy, and technical details of endoscopic retrograde cholangiopancreatography after irreversible electroporation for locally advanced pancreatic cancer. J Gastrointest Surg. 2020;24(5):1077–108. https://doi.org/10.1007/s11605-019-04223-y.

    Article  PubMed  Google Scholar 

  70. Lundy M, Garland-Kledzik M, Shen P. Arterio-enteric fistula after irreversible electroporation. Am Surg. 2019;85:e55–7.

    PubMed  Google Scholar 

  71. Rombouts SJE, et al. Computed tomography findings after radiofrequency ablation in locally advanced pancreatic cancer. Abdom Radiol. 2018;43:2702–11.

    Google Scholar 

  72. Akinwande O, Ahmad SS, Van Meter T, Schulz B, Martin RCG. CT findings of patients treated with irreversible electroporation for locally advanced pancreatic cancer. J Oncol. 2015;2015:1–8.

    Google Scholar 

  73. Paiella S, et al. Radiofrequency ablation for locally advanced pancreatic cancer: SMAD4 analysis segregates a responsive subgroup of patients. Langenbecks Arch Surg. 2018;403(2):213–20. https://doi.org/10.1007/s00423-017-1627-0.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital Trust, Verona, Italy

    Roberto Salvia, Laura Addari & Salvatore Paiella

Authors
  1. Roberto Salvia
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Addari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Salvatore Paiella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Roberto Salvia .

Editor information

Editors and Affiliations

  1. Stavanger University Hospital, The University of Bergen, Bergen, Norway

    Kjetil Søreide

  2. Chirurgie (VTT), Innsbruck Medical University, Innsbruck, Tirol, Austria

    Stefan Stättner

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Salvia, R., Addari, L., Paiella, S. (2021). Role of Ablation Technologies in Locally Advanced Pancreatic Cancer. In: Søreide, K., Stättner, S. (eds) Textbook of Pancreatic Cancer. Springer, Cham. https://doi.org/10.1007/978-3-030-53786-9_82

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-53786-9_82

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-53785-2

  • Online ISBN: 978-3-030-53786-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation